DGAP-News: Canabo Medical Receives $310,000 Grant for Large Opioid Reduction Study

Nachricht vom 05.10.2017 (www.4investors.de) -

DGAP-News: Canabo Medical Inc. / Key word(s): Miscellaneous

Canabo Medical Receives $310,000 Grant for Large Opioid Reduction Study
05.10.2017 / 14:00

The issuer is solely responsible for the content of this announcement.

Vancouver, British Columbia--(Newsfile Corp. - October 5, 2017) - Canabo Medical Inc. (TSXV: CMM) (OTCQB: CAMDF) ('Canabo' or the 'Company') is pleased to report that it will receive a $310,000.00 Research Grant to conduct a study on the reduction of opioids for patients prescribed medical cannabis.The study, perhaps the largest of its kind, will involve 1,000 patients currently using opioids to manage chronic pain. It will examine whether the use of opioids among patients experiencing chronic pain increase or decrease following the prescription of medical cannabis. Opioid deaths are one of the most serious concerns facing physicians in Canada and around the world. John Philpott, Canabo's CEO commented: 'We are delighted to play a leading role in this type of research in Canada. The study's methodology has been already been approved by the Ethics Review Board at Acadia University which will greatly assist in having the study's results published in Medical Journals across Canada and around the world. We believe this is just the beginning for other such research contracts'. In addition, The Company wishes to announce that, subject to TSX Venture Exchange approval, it has granted incentive stock options to certain directors, officers, and consultants to purchase up to an aggregate of 1,000,000 common shares exercisable on or before October 4, 2022 at a price of 0.45c per share.About the Company Canabo wholly owns and operates Cannabinoid Medical Clinics, or CMClinics, Canada's largest physician led referral-only clinics for medical cannabis. Established in 2014, Canabo now has 19 clinics across Canada, with additional locations planned to open in 2017. Canabo operates referral-only medical clinics dedicated to evaluating the suitability of prescribing, and monitoring cannabinoid treatments for patients suffering from chronic pain and disabling illnesses. Clinics operated by Canabo are staffed by physicians and qualified health care practitioners specifically trained to assess patient suitability for cannabinoid treatment, recommend treatment regimes, and monitor treatment progress.Forward Looking StatementsExcept for historical information, this press release contains forward-looking statements, which reflect Canabo Medical Inc.'s current expectations regarding future events. These forward-looking statements involve known and unknown risks and uncertainties that could cause Canabo's actual results to differ materially from those statements. Those risks and uncertainties include, but are not limited to, the Company's ability to access capital, the successful and timely completion of opening clinics, regulatory changes, competition, approvals and other business and industry risks.The forward-looking statements in this press release are also based on a number of assumptions which may prove to be incorrect. Forward-looking statements contained in this press release represent views only as of the date of this release and are presented for the purpose of assisting potential investors in understanding Canabo's business and may not be appropriate for other purposes. Canabo does not undertake to update forward-looking statements, whether written or oral, that may be made from time to time by or on its behalf, except as required under applicable securities legislation. Investors are cautioned not to rely on these forward-looking statements and are encouraged to consult with a professional investment advisor.Readers are cautioned that the foregoing list is not exhaustive. Readers are further cautioned not to place undue reliance on forward-looking statements, as there can be no assurance that the plans, intentions or expectations upon which they are placed will occur. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement.For further information, please contact:Ms. Bianca MüllerTelephone: +1-902-334-1700Email: media@cmclinic.cawww.canabocorp.comNeither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this news release.

Click on, or paste the following link into your web browser, to view
the associated documents


05.10.2017 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.The issuer is solely responsible for the content of this announcement.The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at www.dgap.de

Canabo Medical Inc.


End of News
DGAP News Service

616237  05.10.2017 

PfeilbuttonSTARAMBA SE: „Das Potenzial für STARAMBA.spaces ist riesig“ - Exklusiv-Interview
PfeilbuttonAnleihe-Emission von Euges: „Wollen eine Vertrauensgrundlage aufbauen“ - Exklusiv-Interview!
PfeilbuttonBitcoins, Tulpen und die Lust auf schnelles Geld
PfeilbuttonNanogate: „Nächster Wachstumssprung“ - Exklusiv-Interview mit Ralf Zastrau
PfeilbuttonErgomed: „Evotecs fantastischer Erfolg ist ein positives Signal“ - Exklusiv-Interview

+++ Exklusive Interviews und Analysen - gratis in Ihre Mailbox! +++

Tragen Sie sich jetzt für unseren kostenlosen 4investors Newsletter ein.

Bestätigungslink nicht per Mail bekommen? Bitte kontrollieren Sie Ihren Spamordner!

Der 4investors Newsletter erscheint unregelmäßig, i.d.R. 2 bis 6 Mal pro Monat. Wir geben ihre Mailadresse an keinen Dritten weiter! Sie können den kostenlosen 4investors Newsletter jederzeit problemlos wieder abbestellen.
comments powered by Disqus

Aktuelle Nachrichten aus der 4investors-Redaktion

11.12.2017 - paragon meldet Übernahme
11.12.2017 - Commerzbank Aktie: Das sieht sehr gut aus, aber…
11.12.2017 - Steinhoff Aktie: Ein paar Daten für Trader
11.12.2017 - STARAMBA SE: „Das Potenzial für STARAMBA.spaces ist riesig“
11.12.2017 - HolidayCheck erwartet operativen Gewinn für 2017
11.12.2017 - Evotec Aktie: Steht der Ausbruch bevor? Aktuelle News!
11.12.2017 - Axel Springer will sich von aufeminin trennen
11.12.2017 - Steinhoff: Sehr interessante News!
11.12.2017 - Staramba bereitet sich auf Staramba.spaces vor
11.12.2017 - BMW: China stützt das Absatzwachstum


11.12.2017 - Commerzbank Aktie: Das sieht sehr gut aus, aber…
11.12.2017 - Steinhoff Aktie: Ein paar Daten für Trader
11.12.2017 - Evotec Aktie: Steht der Ausbruch bevor? Aktuelle News!
11.12.2017 - Dialog Semiconductor Aktie: Crash vorbei?
08.12.2017 - Zeal Network Aktie: Trendwende nach der Baisse in Sicht?
08.12.2017 - Evotec Aktie: Jetzt kommt Schwung in die Sache!
08.12.2017 - First Sensor Aktie: Treffer! Und nun?
08.12.2017 - Commerzbank Aktie: Achtung, Kaufsignal!
08.12.2017 - Deutsche Bank Aktie: Eine ganz, ganz wichtige Entscheidung
08.12.2017 - Dialog Semiconductor Aktie: Achtung, Bodenbildung?


11.12.2017 - Unicredit Aktie fair bewertet? Das sagen Analysten!
11.12.2017 - Deutsche Bank Aktie: Vorsicht, Bullenfalle?
11.12.2017 - Wacker Chemie: Deutsche Bank schiebt die Aktie an
11.12.2017 - Bayer Aktie: Zwei neue Expertenstimmen
11.12.2017 - Medigene: 19 Euro sind das Ziel
11.12.2017 - Wirecard: Kaufen nach der Ankündigung
11.12.2017 - Aurubis: Steigendes Kursziel
11.12.2017 - Siemens: IPO sorgt für Hochstufung
11.12.2017 - Allianz: Doppelte Hochstufung der Aktie
08.12.2017 - ProSiebenSat.1: Noch überwiegt die Zurückhaltung


11.12.2017 - ICO – Das smartere Crowdfunding oder nur ein vorübergehender Hype?
11.12.2017 - Apple Aktie: Abwärtstrend angesteuert - UBS Kolumne
11.12.2017 - DAX: Ausbruch über 13.000 Punkte in trockenen Tüchern - UBS Kolumne
08.12.2017 - Bitcoins, Tulpen und die Lust auf schnelles Geld
08.12.2017 - USA: Starker Beschäftigungsaufbau, nur schwacher Lohndruck! - Nord LB Kolumne
08.12.2017 - China Außenhandel: Binnendynamik (noch) robust; Made in China gefragt - Nord LB Kolumne
08.12.2017 - Risk-off zum Wochenausklang dürfte vermutlich kursstützend wirken - National-Bank Kolumne
08.12.2017 - Bayer Aktie: An massiver Unterstützung angelangt - UBS Kolumne
08.12.2017 - DAX: Es fehlen frische Impulse - UBS Kolumne
08.12.2017 - Aufschwung in Deutschland weiter intakt - Commerzbank Kolumne


All Right Reserved by minimalthemes - ©2014 Stoffels & Barck GbR